Prescription of DPP-4 Inhibitors to Patients With Adult Type 2 Diabetes Mellitus and Creatinine Clearance >50 mL/min: The UK Primary Care Experience.

Abstract

The aim of the study was to examine the extent to which patients with type 2 diabetes mellitus (T2DM) initiating a dipeptidyl peptidase 4 (DPP-4) inhibitor, who had no recorded objective evidence to justify dose adjustment, were initiated on the manufacturer-specified dose. Adopting a cross-sectional study design and using data from the UK General Practice, this study showed that at least 10% of patients with T2DM and a creatinine clearance level >50 mL/min initiating treatment with a DPP-4 inhibitor were prescribed a dose lower than specified in the Summary of Product Characteristics. This study provides further insights regarding DPP-4 inhibitor dose selection with respect to manufacturer specification in relation to renal function.

• Authors: Dionysis Spanopoulos, Brendan Barrett, Michael Busse, Toni Roman, Chris Poole
• Journal: Clinical therapeutics (Clin Ther) Vol. 40 Issue 8 Pg. 1424-1428.e4 (08 2018) ISSN: 1879-114X [Electronic] United States
• PMID: 30049504 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Creatinine

Topics

• Creatinine (blood)
• Cross-Sectional Studies
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (administration & dosage)
• Humans
• Hypoglycemic Agents (administration & dosage)
• Primary Health Care (statistics & numerical data)
• Renal Insufficiency, Chronic (complications, physiopathology)
• United Kingdom